Lumos Diagnostics CEO Doug Ward Announces Expanded Distribution for FebriDx® and New Market Entries

Proactive - Interviews for investors

Lumos Diagnostics CEO Doug Ward joined Steve Darling from Proactive to share significant updates about the company’s progress and expansion. Lumos Diagnostics specializes in providing rapid, cost-effective, and comprehensive point-of-care diagnostic test solutions, aiding healthcare professionals in accurately diagnosing and managing medical conditions. The company also offers customized assay development and manufacturing services for point-of-care tests, along with proprietary digital reader platforms. Ward announced that Lumos Diagnostics has extended its agreement with Henry Schein Europe, which will now expand the distribution of its flagship product, FebriDx®, into Belgium. Henry Schein, Inc., the world’s largest provider of healthcare solutions to office-based dental and medical practitioners, currently distributes the FebriDx test in the UK, Spain, Portugal, the Netherlands, and the US. Henry Schein’s Medical business entered the Belgian market in 2023, specifically targeting general practitioners and midwives. In addition to the European expansion, Ward shared that FebriDx is now available to healthcare practitioners in Australia and New Zealand. This follows the signing of a distribution agreement with Regional Health Care Group, a Henry Schein company in Australia and New Zealand. FebriDx® is a rapid point-of-care test designed to differentiate viral from bacterial acute respiratory infections. The test delivers results within 10 minutes from a fingerstick blood sample, enabling healthcare providers to quickly and accurately manage infectious patients in various settings, including Primary Care, Urgent Care, Emergency Departments, Paediatrics, and other Outpatient environments. Ward expressed enthusiasm about these new agreements, highlighting the importance of rapid diagnostic tools in improving patient care and outcomes. The expanded distribution agreements underscore Lumos Diagnostics' commitment to broadening its market presence and making its innovative diagnostic solutions accessible to more healthcare professionals worldwide. These strategic moves position Lumos Diagnostics to significantly impact the global healthcare landscape by providing essential tools for the rapid and accurate diagnosis of infectious diseases. The company continues to focus on innovation, quality, and expanding its reach to meet the growing demand for effective point-of-care diagnostic solutions. #proactiveinvestors #lumosdiagnostics #MedicalDiagnostics, #HealthcareInnovation, #LateralFlowTests, #COVID19Testing, #FDAApproval, #GlobalHealthcare, #MedicalTechnology, #PatientCare, #AntibioticResistance, #FiberxTest, #HealthcareGrowth, #MedicalResearch, #DiagnosticsMarket, #HealthcareDistribution, #MedicalPartnerships, #DiagnosticTests, #HealthcareSolutions, #InfectionTesting, #ElectronicHealthRecords #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews